03759 PHARMARON
Closed Add to Porfolio| Key Financial Ratio (Fiscal Year: 12/2025) | |||
| Current | 0.93X | Oper Margin | 15.9% |
|---|---|---|---|
| LT Debt/Equity | 14.3% | Net Margin | 11.8% |
| Total Debt/Equity | 46.7% | Return on Equity | 11.1% |
| Price/Book | 2.22X | Return on Assets | 6.1% |
| (HKD 20.980) | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
| Net Profit (MHKD) | 1,852.09 | 1,907.23 | 1,764.73 | 1,540.64 | 2,031.20 |
|---|---|---|---|---|---|
| Net Profit Growth (%) | -2.9 | +8.1 | +14.5 | -24.2 | +46.1 |
| Earnings Per Share (HKD) | 1.051 | 1.078 | 0.996 | 0.869 | 1.141 |
| Earnings Per Share Growth (%) | -2.5 | +8.2 | +14.6 | -23.8 | +45.9 |
| Dividend Per Share (HKD) | 0.223 | 0.219 | 0.220 | 0.219 | 0.235 |
| P/E* (X) | 19.96 | 19.47 | 21.07 | 24.15 | 18.39 |
| Yield (%) | 1.06 | 1.04 | 1.05 | 1.04 | 1.12 |
| Dividend Share (%) | 21.18 | 20.30 | 22.08 | 25.22 | 20.58 |
| Book NAV (HKD) | 9.468 | 8.178 | 7.746 | 6.620 | 6.934 |
| Auditors' Opinion | N/A | Unqualified | Unqualified | Unqualified | Unqualified |
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2026-04-02 21:40:20
Latest Result
| (RMBMn) | 2025-12 | 2024-12 | Chg* (%) | 2023-12 |
| Cover Period (mths) | 12 | 12 | NA | 12 |
|---|---|---|---|---|
| Turnover | 14,095 | 12,276 | +14.8 | 11,538 |
| Operating Result | 2,048 | 2,249 | -8.9 | 1,841 |
| Associates | -135.612 | -123.256 | +10.0 | -2.084 |
| Profit Before Taxation | 1,913 | 2,091 | -8.5 | 1,838 |
| Taxation | 357.524 | 377.104 | -5.2 | 256.106 |
| Profit /( Loss) After Taxation | 1,555 | 1,714 | -9.3 | 1,582 |
| Minority Interests | -108.713 | -79.192 | +37.3 | -19.315 |
| Net Profit | 1,664 | 1,793 | -7.2 | 1,601 |
| Earnings Per Share () | 1.0511 | 1.0777 | -2.5 | 0.9957 |
| Dividend Per Share () | 0.2226 | 0.2188 | +1.7 | 0.2199 |
| Announcement Date | 2026-03-30 | 2025-03-26 | NA | 2024-03-27 |
* Annualised
Last Update Time: 2026-04-02 21:40:25
